Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Lumito demonstrates successful integration of SCIZYS® within automated laboratory workflow

LUMITORegulatory press release21.09.2026 klo 09.30
Download the release

Lumito AB (publ) ("Lumito" or the "Company") announces the successful integration of the Company's SCIZYS® Erbium kit with the automated laboratory platform for staining tissue samples from CliniSciences S.A.S (“CliniSciences”). The tests were conducted at CliniSciences using Lumito's SCIZYS® Erbium kit and produced high-quality images without prior protocol optimisation. The integration represents an important milestone in Lumitos commersialisation efforts to offer SCIZYS® within existing automated laboratory workflows. This can simplify use and contribute to broader commercial adoption of Lumito's technology.

An easier way to use SCIZYS®
Automated laboratory platforms are increasingly becoming standard tools in both research and clinical laboratories. By demonstrating compatibility of SCIZYS® with the PA-3600 instrument, several steps are automated in analysis of tissue samples – instead of laboratory personnel performing the steps manually, the system can carry them out according to a pre-programmed workflow.

The test, conducted independently by CliniSciences at its facilities and using Lumito’s Scan-as-a-Service offering, demonstrates that the PA-3600 instrument for research use only (RUO) can be easily integrated and used with the SCIZYS® Erbium kit. The availability of a ready-to-use workflow reduces implementation time and lowers the threshold for laboratories adopting SCIZYS®, making the technology more accessible to a broader user base.

"It was great to see how well it worked without any optimizations. The method is very straightforward, making it easy to implement in an automated workflow", says Jonas Falgén, Business Development Director of CliniSciences.

"Compatibility with established automation platforms is an important part of Lumito’s strategy to expand the use, of SCIZYS®. Being able to offer our Erbium kit together with the CliniSciences autostainer PA-3600 is therefore an important step in the continued commercialization of SCIZYS®. It also creates opportunities for joint marketing activities and increased exposure to laboratories that are in the process of start using, or are already using established automation platforms", says Sanna Wallenborg, CEO of Lumito.

Increased potential to reach more laboratories
For Lumito, compatibility with automated systems is an important part of the Companys strategy to scale the use of SCIZYS®. The more easily the technology can be integrated into laboratories' existing workflows, the lower the barrier to adoption for new users.

CliniSciences S.A.S., is an international company with operations and commercial presence across several major European markets. This creates potential opportunities for increased market presence for PA-3600 and, over time, also for Lumito's technology. CliniSciences is also working to establish its solutions within research at hospitals, with the potential for subsequent clinical use. For Lumito, this could over time create additional opportunities to introduce SCIZYS® into new laboratory environments.

Lumito's goal is for SCIZYS® to be as easy as possible to use within laboratories' existing workflows. The test with PA-3600 represents another step in that direction.

For further information, please contact:


Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Growth Market under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments
Lumito demonstrates successful integration of SCIZYS® within automated laboratory workflow